We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Simple and Inexpensive Ebola Virus Disease Test Developed

By LabMedica International staff writers
Posted on 21 May 2019
Image: A digitally colorized, transmission electron microscopic (TEM) image, which reveals some of the ultrastructural morphology displayed by an Ebola virus virion (Photo courtesy of Cynthia Goldsmith / CDC).
Image: A digitally colorized, transmission electron microscopic (TEM) image, which reveals some of the ultrastructural morphology displayed by an Ebola virus virion (Photo courtesy of Cynthia Goldsmith / CDC).
Ebola and Marburg viruses can cause severe bleeding and organ failure, with fatality rates reaching 90% in some outbreaks. The diseases spread through direct contact with bodily fluids of an infected person, monkey, gorilla, chimpanzee or bat.

Early symptoms of Ebola and Marburg, include fever, headache and diarrhea, and mimic more common diseases, so there's a critical need for a rapid diagnostic test. Such a test could help in efforts to limit outbreaks by quickly quarantining infected persons. But existing diagnostic tests either are inaccurate or are expensive and require extensive training to administer.

Scientists at the Loyola University Health System (Maywood, IL, USA) have generated a panel of mouse single-chain Fv-antibodies (scFvs) to filovirus glycoproteins (GPs) using cell-free ribosome display and determined their cross-reactivity profiles to all known filovirus species. Antibodies could be the key to diagnosing Ebola and Marburg viruses. An antibody is a Y-shaped protein made by the immune system. When a virus or other pathogen invades the body, antibodies mark it for the immune system to destroy.

The team used a technology called cell-free ribosome display, and generated two synthetic antibodies that bind to all six Ebola and Marburg viruses. The study involved the use of non-hazardous proteins that sit on the surface of Ebola and Marburg viruses. Because the actual viruses were not used in the study, there was no risk of infection to the scientists or the public. The antibodies, which are inexpensive to produce, potentially could be used in a simple filter paper test to detect Ebola virus and the related Marburg virus. If the filter paper turns color, the virus is present. The study was published on May 6, 2019, in the American Journal of Tropical Medicine & Hygiene.

Related Links:
Loyola University Health System

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Manual Pipetting Aid
Pipette Controllers macro
New
Gold Member
Platelet Function Analyzer
AGGRENG-40

Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more